Potential implications of PSA-testing for asymptomatic prostate cancer include the problem that 23-43% of these cancers are clinically insignificant, while men with clinically significant disease may be aware of their diagnosis for longer but with no survival benefit [10, 11]. This evidence concerns the gene KLK3 and prostate cancer.